...The companies partnered to use KineMed’s kinetic biomarker technology to discover and develop biomarkers. The companies...
...will target cardiovascular, metabolic and neurology areas. Pfizer said it has not selected targets yet. KineMed...
...receive an upfront payment and R&D funding and is eligible for development and regulatory milestones. KineMed’s...

...Biopharma Forest granted KineMed exclusive, worldwide rights, except Japan, Korea, Taiwan and China, to develop and...
...and China, to develop and commercialize synthetic ghrelin for all indications except amyotrophic lateral sclerosis. KineMed...
...receive milestones, plus royalties. The company plans to start a Phase II trial next year. KineMed...

...The companies partnered to use KineMed’s proteomics technology to evaluate the physiological effects of Pronutria’s biologics...
...effects of Pronutria’s biologics that restore cellular hemostasis. The companies did not disclose financial details. KineMed Inc....

...& Co. Ltd. Note: KineMed withdrew its IPO on NASDAQ, citing “market conditions.” Last month, KineMed...
...up to $50.9 million, with H.C. Wainwright; MKM Dillon; and Dawson James Securities as underwriters. KineMed...

...Biomarker discovery company KineMed Inc. (Emeryville, Calif.) withdrew its IPO on NASDAQ, citing "market conditions." The company...
...NASDAQ, citing "market conditions." The company declined to comment on future financing plans. Last month, KineMed...
...operating loss of $1.7 million. As of March 31, KineMed had $7.3 million in cash. KineMed...

...Catalent Inc. (NYSE) 1/24/14 Up to $100M Mkt (services) Microlin Bio Inc. 1/10/14 $30M Preclin KineMed Inc....

...The companies again extended a 2012 non-exclusive research deal to use KineMed's Dynamic Proteomics technology to...
...and KineMed could not be reached (see BioCentury, Feb. 6, 2012 & April 1, 2013). KineMed Inc....

...to $33.8 million Shares: 4.5 million Price: $6.50-$7.50 Underwriter: Feltl; MLV; Laidlaw Overallotment: 675,000 Note: KineMed...
...up to $50.9 million, with H.C. Wainwright; MKM Dillon; and Dawson James Securities as underwriters. KineMed...

...Biomarker discovery company KineMed Inc. (Emeryville, Calif.) amended its IPO on NASDAQ and now plans to sell...
...million and be valued at $113.8 million. Feltl and Co.; MLV; and Laidlaw are underwriters. KineMed...
...NYSE:PFE) and AstraZeneca plc (LSE:AZN; NYSE:AZN), as well as collaborations with not-for-profits and government agencies. KineMed...

...KineMed and the foundation extended a May 2012 deal using KineMed's isotopic labeling and Dynamic Proteomics...
...nucleic acid-based approach. The partners declined to disclose financial details (see BioCentury, May 21, 2012). KineMed Inc....